These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30915153)

  • 21. Logistic Regression Likelihood Ratio Test Analysis for Detecting Signals of Adverse Events in Post-market Safety Surveillance.
    Nam K; Henderson NC; Rohan P; Woo EJ; Russek-Cohen E
    J Biopharm Stat; 2017; 27(6):990-1008. PubMed ID: 28346083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple self-controlled case series for large-scale longitudinal observational databases.
    Simpson SE; Madigan D; Zorych I; Schuemie MJ; Ryan PB; Suchard MA
    Biometrics; 2013 Dec; 69(4):893-902. PubMed ID: 24117144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postmarketing Safety Profile of Subcutaneous Interferon Beta-1a Given 3 Times Weekly: A Retrospective Administrative Claims Analysis.
    Smith MY; Sabidó-Espin M; Trochanov A; Samuelson M; Guedes S; Corvino FA; Richy FF
    J Manag Care Spec Pharm; 2015 Aug; 21(8):650-60. PubMed ID: 26233537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of Action, Pharmacokinetics, Efficacy, and Safety of Transarterial Therapies Using Ethiodized Oil: Preclinical Review in Liver Cancer Models.
    Gaba RC; Schwind RM; Ballet S
    J Vasc Interv Radiol; 2018 Mar; 29(3):413-424. PubMed ID: 29289495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Illusions of objectivity and a recommendation for reporting data mining results.
    Hauben M; Reich L; Gerrits CM; Younus M
    Eur J Clin Pharmacol; 2007 May; 63(5):517-21. PubMed ID: 17364192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety related drug-labelling changes: findings from two data mining algorithms.
    Hauben M; Reich L
    Drug Saf; 2004; 27(10):735-44. PubMed ID: 15350157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Signal selection and follow-up in pharmacovigilance.
    Meyboom RH; Lindquist M; Egberts AC; Edwards IR
    Drug Saf; 2002; 25(6):459-65. PubMed ID: 12071784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
    Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
    Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
    Zink RC; Huang Q; Zhang LY; Bao WJ
    Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of exposure accrual on sequential postmarket evaluations: a simulation study.
    Maro JC; Brown JS
    Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1184-91. PubMed ID: 22020903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug safety data mining with a tree-based scan statistic.
    Kulldorff M; Dashevsky I; Avery TR; Chan AK; Davis RL; Graham D; Platt R; Andrade SE; Boudreau D; Gunter MJ; Herrinton LJ; Pawloski PA; Raebel MA; Roblin D; Brown JS
    Pharmacoepidemiol Drug Saf; 2013 May; 22(5):517-23. PubMed ID: 23512870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous sequential boundaries for vaccine safety surveillance.
    Li R; Stewart B; Weintraub E; McNeil MM
    Stat Med; 2014 Aug; 33(19):3387-97. PubMed ID: 24691986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Criteria revision and performance comparison of three methods of signal detection applied to the spontaneous reporting database of a pharmaceutical manufacturer.
    Matsushita Y; Kuroda Y; Niwa S; Sonehara S; Hamada C; Yoshimura I
    Drug Saf; 2007; 30(8):715-26. PubMed ID: 17696584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electronic Health Data for Postmarket Surveillance: A Vision Not Realized.
    Moore TJ; Furberg CD
    Drug Saf; 2015 Jul; 38(7):601-10. PubMed ID: 26025018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian approach for clinical trial safety data using an Ising prior.
    McEvoy BW; Nandy RR; Tiwari RC
    Biometrics; 2013 Sep; 69(3):661-72. PubMed ID: 23845253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.
    Xu Y; Zhou X; Suehs BT; Hartzema AG; Kahn MG; Moride Y; Sauer BC; Liu Q; Moll K; Pasquale MK; Nair VP; Bate A
    Drug Saf; 2015 Aug; 38(8):749-65. PubMed ID: 26055920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative methods in pharmacovigilance: focus on signal detection.
    Hauben M; Zhou X
    Drug Saf; 2003; 26(3):159-86. PubMed ID: 12580646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress in toxinformatics: the challenge of predicting acute toxicity.
    Zmuidinavicius D; Japertas P; Petrauskas A; Didziapetris R
    Curr Top Med Chem; 2003; 3(11):1301-14. PubMed ID: 12769707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
    Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
    J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance.
    Silva IR; Kulldorff M
    Biometrics; 2015 Sep; 71(3):851-8. PubMed ID: 26011024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.